Overview
Osteoporosis means “porous bone.” In osteoporosis, the structure of the bone becomes weaker and less stable. The bones in the spine, hip, and wrist are usually affected. Women are more likely than men to be diagnosed with osteoporosis because it is common after menopause. Most people do not notice symptoms until a bone breaks. A scan of the bone can calculate the bone density to diagnosis osteoporosis. Most patients will need to take supplements of calcium and vitamin D to help strengthen their bones, but other medications may be needed based on the results of the bone density test.
Drug Therapies
-
Bonsity (teriparatide)
Bonsity (teriparatide) is a synthetic form of the natural human parathyroid hormone. Given by once-daily injection, it increases bone mineral density and strength to reduce the risk of fracture in patients with osteoporosis.Manufacturer:AlvogenRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:833-330-0806Approved Indication:
- treatment of postmeopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to over available osteoporosis therapyy
- increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
- treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
Conditions:
- Osteoporosis
-
Forteo (teriparatide)
Forteo (teriparatide) is a synthetic form of the natural human parathyroid hormone. Given by once-daily injection, it increases bone mineral density and strength to reduce the risk of fracture in patients with osteoporosis.Manufacturer:LillyRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-866-568-8942Approved Indication:
- treatment of postmeopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to over available osteoporosis therapyy
- increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
- treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy
Conditions:
- Osteoporosis
-
ibandronate
Ibandronate is a bisphosphonate medication that blocks the action of osteoclasts, cells responsible for bone breakdown, to strengthen bone and reduce the risk of fractures in post-menopausal women with osteoporosis.Manufacturer:MiscRoute of Administration:Oral, IntravenousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
treatment and prevention of osteoporosis in postmenopausal women
Conditions:
- Osteoporosis
-
Jubbonti (denosumab-bbdz)
Jubbonti (denosumab-bbdz) is an FDA-approved interchangeable biosimilar to Prolia. Like Prolia, Jubbonti is a monoclonal antibody that blocks the action of the protein RANKL to decrease bone breakdown.Manufacturer:SandozRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-800-954-9128Approved Indication:
- treatment of postmenopausal women with osteoporosis at high risk for fracture
- to increase bone mass in men with osteoporosis at high risk for fracture
- treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Conditions:
- Osteoporosis
Therapeutic Area:
- Endocrinology
- Geriatrics
- Oncology
-
Prolia (denosumab)
Prolia (denosumab) is the original, or “reference,” denosumab product. Denosumab is a monoclonal antibody that blocks the action of the protein RANKL to decrease bone breakdown.Manufacturer:AmgenRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-866-264-2778Approved Indication:
- treatment of postmenopausal women with osteoporosis at high risk for fracture
- to increase bone mass in men with osteoporosis at high risk for fracture
- treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Conditions:
- Osteoporosis
Therapeutic Area:
- Endocrinology
- Geriatrics
- Oncology
-
Reclast (zoledronic acid)
Reclast (zoledronic acid) is a bisphosphonate medication that blocks the action of osteoclasts, cells responsible for bone breakdown, to strengthen bone and reduce the risk of fractures in men and women with osteoporosis.Manufacturer:NovartisRoute of Administration:IntravenousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment and prevention of postmenopausal osteoporosis
- treatment to increase bone mass in men with osteoporosis
- treatment and prevention of glucocorticoid-induced osteoporosis
- treatment of Paget’s disease of bone in men and women
Conditions:
- Osteoporosis
- Paget’s Disease
Therapeutic Area:
- Endocrinology
- Geriatrics
Resources
Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.
Stay Connected
Get the latest news and updates